Merck Soars to New High on Strong Pipeline and mRNA Cancer Breakthrough

Merck's stock price has reached a new 52-week high after the company's positive results in its innovative new drug pipeline. The pharmaceutical giant's shares closed at $152.55 on the New York Stock Exchange, up $3.56 or 2.39% from the previous trading day.

The company's success can be attributed to the phase 3 clinical trials of its mRNA cancer treatment, Intismeran Autogen, in collaboration with Moderna. The trial showed a significantly longer survival period without recurrence of cancer or metastasis to other organs for patients with high-risk melanoma.

Morgan Stanley has raised its investment opinion on Merck from Neutral to Overweight and increased its target price to $179 from $116, predicting that the company's next-generation new drug pipeline and capital allocation strategy will grow further. The analysts also expect Merck's mRNA cancer vaccine to open a new horizon for next-generation precision chemotherapy.